ムコ多糖症II型(MPS II)(ハンター症候群)(Mucopolysaccharidosis II (Hunter Syndrome))：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Overview 7
Therapeutics Development 8
Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) – Overview 8
Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) – Comparative Analysis 9
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) – Therapeutics under Development by Companies 10
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) – Products under Development by Companies 13
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) – Companies Involved in Therapeutics Development 14
ArmaGen Technologies, Inc. 14
biOasis Technologies Inc. 15
Fate Therapeutics, Inc. 16
Green Cross Corporation 17
JCR Pharmaceuticals Co., Ltd. 18
Sangamo BioSciences, Inc. 19
Shire Plc 20
Synageva BioPharma Corp. 21
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AGT-182 – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
FT-1050 – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Gene Therapy to Target Iduronate 2-Sulfatase for Hunter Syndrome – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
idursulfase – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
idursulfase – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
JR-032 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
MTf-I2S – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MTfp-I2S – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Next Generation biologics for Pompe, Fabry and Hunter – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SHP-631 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) – Recent Pipeline Updates 42
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) – Dormant Projects 46
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) – Product Development Milestones 47
Featured News & Press Releases 47
Mar 10, 2015: PacificGMP and ArmaGen Announce Successful Manufacture of ArmaGen’s investigational enzyme replacement therapy, AGT-182, for Phase 1 Clinical Trial 47
Dec 11, 2014: ArmaGen Announces FDA Acceptance of IND Application for AGT-182 for the Treatment of Hunter Syndrome 47
Sep 18, 2014: biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation 48
Jun 17, 2014: ArmaGen Receives Notice of Allowance for U.S. Patent Covering Novel Investigational Therapy for Hunter Syndrome 49
Oct 02, 2013: Green Cross Exports Orphan Disease Drug Hunterase to Algeria 50
Jul 18, 2013: ARMAGEN Receives US Orphan Designation For Lead Product AGT-182 50
Apr 08, 2013: Green Cross Announces Publication Of Clinical Trial Paper On Hunter Syndrome Drug Hunterase In International Scientific Press 51
Feb 18, 2013: Green Cross Receives FDA Orphan Drug Designation For Hunterase For Treatment Of Hunter Syndrome 51
Jan 10, 2012: Green Cross Receives Korean Approval For Hunterase 52
Oct 12, 2011: Green Cross Files Application For Korean Approval Of Hunterase For Treatment Of Hunter Syndrome 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55